ClinicalTrials.Veeva

Menu
The trial is taking place at:
G

Global Health Research Center | Miami Lakes, FL

Veeva-enabled site

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (ACHIEVE-1)

Lilly logo

Lilly

Status and phase

Active, not recruiting
Phase 3

Conditions

Type 2 Diabetes

Treatments

Drug: Orforglipron
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05971940
18564
J2A-MC-GZGT (Other Identifier)
U1111-1290-5157 (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.

Enrollment

520 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have Type 2 Diabetes
  • Have HbA1c ≥7.0% (53 mmol/mol) to ≤9.5% (80 mmol/mol) despite diet and exercise treatment, as determined by the central laboratory at screening.
  • Are naïve to insulin therapy except for gestational diabetes or ≤14 days use for acute treatment and have not used any oral or injectable antihyperglycemic medications during the 90 days preceding screening or between screening and randomization.
  • Are of stable weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight other than the lifestyle and/or dietary measures for diabetes treatment.
  • Have a body mass index (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion criteria

  • Have Type 1 Diabetes
  • Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening, or between screening and randomization.
  • Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Have New York Heart Association functional classification IV congestive heart failure.
  • Have acute or chronic pancreatitis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

520 participants in 4 patient groups, including a placebo group

Orforglipron Dose 1
Experimental group
Description:
Participants will receive orforglipron orally.
Treatment:
Drug: Orforglipron
Orforglipron Dose 2
Experimental group
Description:
Participants will receive orforglipron orally.
Treatment:
Drug: Orforglipron
Orforglipron Dose 3
Experimental group
Description:
Participants will receive orforglipron orally.
Treatment:
Drug: Orforglipron
Placebo
Placebo Comparator group
Description:
Participants will receive placebo orally.
Treatment:
Drug: Placebo

Trial contacts and locations

90

Loading...

Central trial contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems